Which statement best describes BRCA1 variant evaluation in unusual family history?

Which statement best describes BRCA1 variant evaluation in unusual family history?

• A. Assess co-segregation with disease, population frequency, in silico predictions, functional data, and consider expert genetic counseling and possible reclassification.
• B. Rely only on population frequency to classify variants.
• C. Use in silico predictions alone to classify variants.
• D. Ignore functional data in variant assessment.

Answer: (B)

Evaluating BRCA1 variants in the setting of an unusual family history requires pulling together several lines of evidence to judge whether a variant is pathogenic, likely benign, or of uncertain significance. Population frequency helps separate common polymorphisms from rare variants, but rarity alone doesn’t determine disease risk—some rare variants are harmless, while others are pathogenic. The way the variant segregates with cancer in the family provides direct evidence: if the variant co-segregates with disease across affected relatives, that supports its pathogenic role; if it fails to co-segregate, that weakens the case for causality. Functional data are particularly important when family data are inconclusive or the history is atypical. Experimental results showing that a BRCA1 variant impairs DNA repair or other BRCA1 functions offer strong evidence of potential pathogenicity, sometimes overriding ambiguous family data. In silico predictions can add supportive context about potential effects on splicing or protein function, but they are not definitive and can be inaccurate, so they should not be the sole basis for classification. Because interpretations can evolve with new information, expert genetic counseling is essential to integrate all available evidence and consider whether reclassification may be warranted over time. This collaborative approach helps tailor surveillance and management for the patient and at-risk relatives. Relying only on population frequency, or using predictions alone, or ignoring functional data, would miss key pieces of evidence and could lead to incorrect or incomplete risk assessment.

Evaluating BRCA1 variants in the setting of an unusual family history requires pulling together several lines of evidence to judge whether a variant is pathogenic, likely benign, or of uncertain significance. Population frequency helps separate common polymorphisms from rare variants, but rarity alone doesn’t determine disease risk—some rare variants are harmless, while others are pathogenic. The way the variant segregates with cancer in the family provides direct evidence: if the variant co-segregates with disease across affected relatives, that supports its pathogenic role; if it fails to co-segregate, that weakens the case for causality.

Functional data are particularly important when family data are inconclusive or the history is atypical. Experimental results showing that a BRCA1 variant impairs DNA repair or other BRCA1 functions offer strong evidence of potential pathogenicity, sometimes overriding ambiguous family data. In silico predictions can add supportive context about potential effects on splicing or protein function, but they are not definitive and can be inaccurate, so they should not be the sole basis for classification.

Because interpretations can evolve with new information, expert genetic counseling is essential to integrate all available evidence and consider whether reclassification may be warranted over time. This collaborative approach helps tailor surveillance and management for the patient and at-risk relatives.

Relying only on population frequency, or using predictions alone, or ignoring functional data, would miss key pieces of evidence and could lead to incorrect or incomplete risk assessment.